-
公开(公告)号：EP3201227A1
公开(公告)日：2017-08-09
申请号：EP15846994.0
申请日：2015-09-29
发明人： HAYNES, Barton F. , FERRARI, Guido , KOENIG, Scott , JOHNSON, Leslie S. , LAM, Chia-Ying Kao , SUNG, Julia A. , MARGOLIS, David M. , LIU, Liqin , NORDSTROM, Jeffrey, Lee
IPC分类号： C07K16/10
CPC分类号： C07K16/1063 , A61K39/39541 , A61K39/42 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/2812 , C07K16/283 , C07K16/44 , C07K16/468 , C07K2317/31 , C07K2317/52 , C07K2317/626 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76
摘要： The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
摘要翻译： 本发明涉及包含靶向效应细胞的HIV-1包膜靶向臂和臂的双特异性分子，包含这些双特异性分子的组合物和使用方法。 在某些方面，本发明的双特异性分子可结合两种不同细胞上的两种不同靶标或表位，其中第一表位在与第二表位不同的细胞类型上表达，使得双特异性分子可将两种细胞结合在一起 。 在某些方面，本发明的双特异性分子可结合两种不同的细胞，其中双特异性分子包含具有A32,7B2，CH27，CH28或CH44的结合特异性的臂。
-
2.发明公开
公开(公告)号：EP3839044A1
公开(公告)日：2021-06-23
申请号：EP20217972.7
申请日：2014-03-13
申请人： MacroGenics, Inc. , Duke University
发明人： KOENIG, Scott , JOHNSON, Leslie S. , LAM, Chia-Ying Kao , LIU, Liqin , NORDSTROM, Jeffrey Lee , HAYNES, Barton F. , FERRARI, Guido
IPC分类号： C12N5/16 , A61K39/12 , A61K45/00 , A61K39/00 , A61K39/38 , A01N65/00 , C12N7/00 , C12N7/01 , C12N5/07 , C07K16/10
摘要： The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
-
3.发明授权
-
4.发明公开
公开(公告)号：EP2021029A2
公开(公告)日：2009-02-11
申请号：EP07873826.7
申请日：2007-05-25
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling
IPC分类号： A61K39/395 , A61P43/00 , C07H21/04 , C07K16/18 , C12N15/00 , C12N5/06 , C12P21/04 , G01N33/564
CPC分类号： A61K39/39 , A61K2039/505 , A61K2039/55516 , C07K16/283 , C07K2317/24 , C07K2317/34 , C07K2317/52 , G01N33/564 , G01N33/6893 , G01N2800/24
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
-
公开(公告)号：EP3558391A1
公开(公告)日：2019-10-30
申请号：EP17835533.5
申请日：2017-12-21
申请人： Immunogen, Inc. , MacroGenics, Inc.
-
公开(公告)号：EP2714079B2
公开(公告)日：2019-08-28
申请号：EP12789439.2
申请日：2012-05-16
申请人： MacroGenics, Inc.
IPC分类号： A61K39/395 , C07K16/28 , C07K16/32 , C07K16/44
-
7.发明授权
公开(公告)号：EP3030264B1
公开(公告)日：2019-01-09
申请号：EP14834798.2
申请日：2014-08-06
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling , SHAH, Kalpana , BONVINI, Ezio , MOORE, Paul A. , CHEN, Wei
IPC分类号： A61K39/395
-
8.发明公开Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity 审中-公开根据具有减小了毒性单克隆抗体用于治疗自身免疫性疾病的方法
公开(公告)号：EP2815764A1
公开(公告)日：2014-12-24
申请号：EP14166617.2
申请日：2007-06-14
申请人： MACROGENICS, INC.
IPC分类号： A61K39/395 , A61K39/40 , A61K39/21 , A61P37/00 , C07K16/28
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/24 , C07K2317/41 , C07K2317/71
摘要： The present disclosure provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of T cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes ( i.e. type 1 diabetes or insulin-dependent diabetes mellitus (IDDM)) and multiple sclerosis) through the use of anti-human CD3 antibodies. The antibodies of the disclosure are preferably used in low dose dosing regimens, chronic dosing regimens or regimens that involve redosing after a certain period of time. The methods of the disclosure provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the methods of the disclosure provide for use of anti-human CD3 antibodies modified such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译： 本发明提供了治疗，预防，减缓进展，或改善T细胞的症状介导的免疫疾病，特别是自身免疫性疾病（例如，自身免疫性糖尿病（即1型糖尿病或胰岛素依赖型糖尿病（IDDM））和方法 多发性硬化）通过使用抗人CD3抗体。 本公开的抗体在低剂量给药方案优选使用的，慢性的给药方案或方案的一定时间之后也涉及再次给药。 本公开的方法提供了抗体的施用特异性结合所做的人CD3复合物内的ε亚基。 搜索抗体调节T细胞受体/同种异体抗原相互作用，并且因此调节与自身免疫性疾病相关联的T细胞介导的细胞毒性。 另外，本公开的方法提供了使用改性寻求thatthey表现出降低或消除效应子功能和T细胞活化相比于未修饰的抗人CD3抗体的抗人CD3抗体。
-
公开(公告)号：EP2252631A2
公开(公告)日：2010-11-24
申请号：EP09763010.7
申请日：2009-03-25
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling
CPC分类号： C07K16/28 , C07K16/2803 , C07K2317/24 , C07K2317/56
摘要： Chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
-
公开(公告)号：EP3954703A3
公开(公告)日：2022-05-18
申请号：EP21185550.7
申请日：2015-05-29
申请人： MacroGenics, Inc.
发明人： JOHNSON, Leslie S. , HUANG, Ling , CHICHILI, Gurunadh Reddy , SHAH, Kalpana , LAM, Chia-Ying, Kao , BURKE, Stephen, James , LIU, Liqin , MOORE, Paul, A. , BONVINI, Ezio , BARAT, Bhaswati
IPC分类号： C07K16/18 , C07K16/28 , C07K16/30 , A61P1/04 , A61P1/16 , A61P5/00 , A61P9/10 , A61P11/00 , A61P13/10 , A61P13/12 , A61P17/00 , A61P19/00 , A61P21/00 , A61P35/02 , A61P35/00 , A61P35/04 , A61P1/18 , A61P13/00 , A61P13/08 , A61P15/00 , A61P25/00
摘要： The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.038 秒)
